Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.
Oliver GrossJan BoeckhausLutz T WeberHiddo J Lambers HeerspinkJames F SimonRees AhmedChristoph GerstUlrike DuerrFlorian WalkerRalf TostmannJürgen HelmThomas AsendorfTim FriedePublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
DOUBLE PRO-TECT Alport will assess whether SGLT2-inhibitors can safely reduce change from baseline in UACR as a marker for progression of CKD in young patients living with AS.